Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer

Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location

“…Finally, in the present study we chose to include rectal cancer patients in the LS group to be consistent with previous studies. [14][15][16][17][18][19] However, some reports have excluded rectal cancer from the LS CRC group, as rectal tumors may be considered distinct from other LS tumors. 20,22 In sum, data from the current study demonstrated that the prognostic impact of KRAS mutation status after hepatectomy for CRLM varied according to primary CRC location.…”

“…Specifically, several studies have noted that right-sided (RS) versus left-sided (LS) CRC differ in incidence, pathogenesis, genetic susceptibility to neoplastic degeneration, and oncologic outcomes. [14][15][16][17][18][19] Furthermore, these differences in molecular features and prognostic characteristics of the primary lesion may be maintained in the metastatic lesions. 20 For example, two studies recently reported different treatment outcomes for patients undergoing chemotherapy for metastatic CRC according to primary CRC site and KRAS status.…”

Effect of Concomitant Polyethylene Glycol and Celecoxib on Colonic Aberrant Crypt Foci and Tumors in F344 Rats

“…Within the transverse but not the distal colon, however, there was a greater reduction in ACF in rats treated with PEG + celecoxib compared to PEG alone. There is some evidence for different mechanisms underlying sporadic right-versus left-sided human colon cancers (31,32), although we are not aware of similar comparisons in the rat; and the efficacy of celecoxib in tumor prevention has varied depending on the proximal-to-distal location along the intestine in the Min mouse model (12). We detected a similar proportion of tumors in Group I rats as reported, ∼70%, and a more pronounced reduction in tumor number (to 12%) with the addition of celecoxib to PEG treatment.…”

Low Collagenase-1 (MMP-1) and MT1-MMP Expression Levels Are Favourable Survival Markers in Advanced Colorectal Carcinoma

“…Such differences are probably related to the molecular characteristics of the tumours, with the microsatellite instability and methylator phenotypes being associated with right-sided tumours and chromosomal instability with left-sided tumours. We suggest that the higher levels of MMP-1 expression associated with distal tumours may be because of the differing genetic pathways that left-sided and right-sided tumours are thought to take; however, we can only speculate at this time [51, 52, 53]. …”